Why carry out this study?

Atopic dermatitis (AD) often affects multiple body regions and is associated with a high burden for patients when exposed skin areas are involved.

Rapid and effective treatment of AD across multiple body regions is an unmet need, especially in body areas that are difficult to treat, such as the head and neck area.

This post hoc analysis investigated the temporal and regional patterns of clinical improvement in AD with abrocitinib in JADE COMPARE, a phase 3, multicenter, randomized, double-blind, double-dummy trial that evaluated the efficacy and safety of abrocitinib 200 mg once daily, abrocitinib 100 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, and placebo, combined with background medicated topical therapy in adult patients with moderate-to-severe AD.

What was learned from the study?

Eczema Area and Severity Index body region scores significantly improved with abrocitinib 200 mg and 100 mg versus placebo at week 2 and were maintained up to 16 weeks.

Abrocitinib may be useful in patients with AD that affects difficult-to-treat anatomical areas or who require a rapid response.